4646 Background: Chronic inflammation and the subsequent tissutal alterations may play a key role in prostate carcinogenesis. In this way, molecular alterations of the suppressor of cytokine signaling (SOCS) 3, one of the most important inhibitory molecule of the inflammatory signal transduction circuitries, could contribute to explain the pleiotropic role of interleukin (IL)-6 in this type of cancer. Methods: We analyzed the methylation status and mRNA expression of SOCS3 in 20 benign prostate hyperplasias (BPH) and in 51 prostate cancer specimens. After DNA modification with bisulphite, we analyzed the SOCS3 methylation status using Methylation-Specific PCR (MSP-PCR). Hypermethylation was confirmed by sequencing after subcloning. In addition, epigenetic silencing of this gene was also confirmed by real-time PCR. We statistically analyzed the correlation between our results and clinical data. Results: We found that the promoter of SOCS3 was methylated in 39.2% of prostate cancer. On the contrary, all BPH and normal controls had an unmethylated pattern. Real-time analysis showed that in methylated cases mRNA expression for SOCS3 was reduced by 3 and 4 folds as compared to BPH and unmethylated prostate cancer, respectively. Interestingly, SOCS3 mRNA was more expressed in unmethylated prostate cancer than in BPH. Moreover, methylation of SOCS3 promoter significantly associated with intermediate-high grade Gleason score (p=0.0007) and with an unfavorable clinical outcome (p=0.0019). In addition, we found a concordant result in the methylation status of SOCS3 both in biopsies and in prostate after surgical resection. Conclusions: Our data suggest that methylation of SOCS3 may be involved in the pathogenesis of prostate cancer and could identify in the bioptic specimen the subset of tumor with an aggressive behavior. In conclusion, SOC3 methylation could be a new prognostic marker and novel target for therapy. No significant financial relationships to disclose.